Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.

CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.

The sponsor of a clinical trial, which may be a pharmaceutical company or an academic institution, is responsible for submitting information about their study to the ClinicalTrials.gov database.

Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.

On Jan 17, 2024, Windtree Therapeutics announced a licensing deal with Lee's Pharm for its heart failure drug istaroxime in Greater China.

Chipscreen NewWay Initiates Phase 1 Study: Administers Initial Dose of Innovative Dual-Targeting Antibody NWY001 for Advancing Cancer Immune Therapy in Individuals with Progressive Solid Cancers.

The ClinicalTrials.gov database provides information about clinical trials that are currently recruiting or have recently been completed.

InnoCare Pharma has disclosed that the FDA has given approval to proceed with the clinical study for its BCL2 inhibitor, designated as ICP-248.

On January 8, 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion to enhance its Antibody-Drug Conjugate (ADC) portfolio, including promising treatments like ARX517 for metastatic prostate cancer.

AM-Pharma B.V. has started Phase 2 trials treating patients to test its enzyme, ilofotase alfa, for preventing kidney injury post-cardiac surgery.

ClinicalTrials.gov is a public database that contains information on clinical trials conducted around the world.

ExeVir Bio reports its antibodies effectively neutralize current COVID-19 Omicron strains.